(Date:12/2/2008)...y held biopharmaceutical company, today announced ...d investigational product candidate, HZT 501, met ...ary fixed-dose combination product containing ibup... significant reduction in the incidence of non-ste...r gastrointestinal (gastric and/or duodenal) ulcer...
(Date:12/2/2008)...e/ -- /EIN News/ -- EIN News has announced the lau...s on prostate cancer. , , With new advances...ut that information is one of the key components t... growing demand for accurate information about pro...es and drugs to treat it, EIN News is introducing ...
(Date:12/2/2008)...e/ -- EIN News has announced the launch of a new h...er. , , With new advances in medicine, more...n is one of the key components to surviving cancer...r accurate information about lung cancer, its risk...it, EIN News is introducing Lung Cancer News Today...
(Date:12/2/2008)...Newswire/ -- Southern Research Institute -- a not...basic and applied research in the areas of preclin...neering, environmental and energy production -- to...ct from Black & Veatch to help support the U.S...ion Program (BTRP) in the Ukraine. , , The ...
Breaking Medicine News(10 mins):Health News:Horizon Therapeutics announces 2 pivotal HZT-501 Phase 3 trials meet primary endpoints 2Health News:EIN News Introduces 'Prostate Cancer News Today'; Website Offers Information on Risk Factors, Treatment, Drugs 2Health News:EIN News Introduces 'Lung Cancer News Today'; Website Offers Information on Risk Factors, Treatment, Drugs 2Health News:Southern Research Wins $37 Million Black & Veatch Sub-Contract for Biological Threat Reduction Program 2Health News:Southern Research Wins $37 Million Black & Veatch Sub-Contract for Biological Threat Reduction Program 3(Date:12/2/2008)...he United States that are at the highest risk of s...ing enough to the dangers posed by rising temperat...alf century of climate change that has already sig...patterns and has already had widespread ecological...ainty that the United States will experience at le...
(Date:12/2/2008)...than anywhere else in the world. This is having a ...urban environment and effect of cities on rural ar...in Africa,s history is being over-looked. , Joy ...the problem in the current issue of the African J...95% of the African population was rural, today 38%...
(Date:12/2/2008)...Forschungsgemeinschaft (DFG, German Research Found...Centres. They will be initially funded for the nex...ion euros. Among other things, the new Collaborati...ases caused by viruses and bacteria, scarring of t...pics include the optimisation of planning, product...
(Date:12/2/2008)...utrition related topics raises unique challenges n...a new article, a team of researchers use specific ...itations of systematic reviews relevant to nutriti.... , Systematic reviews, also referred to as evi... with pre-specified questions that can be used to ...
Breaking Biology News(10 mins):Most US organizations not adapting to climate change 2Most US organizations not adapting to climate change 3From sheet metal elements to host cells: DFG launches 10 new collaborative research centers 2From sheet metal elements to host cells: DFG launches 10 new collaborative research centers 3From sheet metal elements to host cells: DFG launches 10 new collaborative research centers 4From sheet metal elements to host cells: DFG launches 10 new collaborative research centers 5From sheet metal elements to host cells: DFG launches 10 new collaborative research centers 6From sheet metal elements to host cells: DFG launches 10 new collaborative research centers 7Experts discuss applying systematic review to the field of nutrition 2Novavax to Present Phase I IIa Trial Data Results in an Investor Conference Call on August 26 2008 2871 1Novavax to Present Phase I IIa Trial Data Results in an Investor Conference Call on August 26 2008 2871 2Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout RDEA594 Into Phase 1 Clinical Trial 2867 1Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout RDEA594 Into Phase 1 Clinical Trial 2867 2Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout RDEA594 Into Phase 1 Clinical Trial 2867 3Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout RDEA594 Into Phase 1 Clinical Trial 2867 4Vaxfectin 28R 29 formulated Measles DNA Vaccine Could Address Unmet Need for Infants 7265 1Vaxfectin 28R 29 formulated Measles DNA Vaccine Could Address Unmet Need for Infants 7265 2Vaxfectin 28R 29 formulated Measles DNA Vaccine Could Address Unmet Need for Infants 7265 3Vaxfectin 28R 29 formulated Measles DNA Vaccine Could Address Unmet Need for Infants 7265 4Vaxfectin 28R 29 formulated Measles DNA Vaccine Could Address Unmet Need for Infants 7265 5Arpidas iclaprim MAA Accepted for Review by EMEA 7261 1Arpidas iclaprim MAA Accepted for Review by EMEA 7261 2Arpidas iclaprim MAA Accepted for Review by EMEA 7261 3